Laura A. Navalta is Executive Vice President, Clinical Operations at Elion Therapeutics.

Laura’s extensive background in drug development, coupled with strong knowledge and passion in the clinical operations arena, make her a powerhouse for the company. Laura has over 40 years of industry experience, with global expertise in all phases of clinical trial start-up, oversight, vendor selection & management, quality compliance, as well as regulatory requirements. In addition to infectious disease, Laura’s experience covers a breadth of therapeutic areas, including oncology, cardiovascular & renal, critical care areas, and neurology. Most recently, Laura has held senior executive roles in clinical operations for pharmaceutical & biotechnology organizations, providing critical contributions to multiple drug approvals, including Rezzayo® (2023) for the treatment of candidemia and invasive candidiasis.